Answers are grounded in this paper and cite their sources.
Retrospective cohort study finds specific immune-related adverse events improve survival in advanced melanoma, suggesting lower corticosteroid use preserves treatment efficacy.
Background Programmed cell death protein 1 (PD-1) inhibitors improve survival in advanced melanoma but can induce immune-related adverse events (irAEs). IrAEs have been linked to better outcomes. However, it remains unclear whether specific irAE types drive this effect and how corticosteroid treatment of irAEs influences survival. Methods A seven-year retrospective cohort study of 301 patients with advanced cutaneous melanoma treated with single-agent PD-1 inhibition at Sahlgrenska University Hospital. irAEs were identified using CTCAE v4.0/v5.0, and irAEs requiring systemic corticosteroids or endocrine replacement therapy were included. Corticosteroid therapy was categorized as low dose (≤0.5 mg/kg prednisolone equivalent) or high dose (>0.5 mg/kg). Overall survival (OS) was assessed using Kaplan–Meier and Cox models, including time-dependent analyses to address immortal time bias. Results Patients with irAE (109 of 301 patients) had longer OS than those without irAEs. Of the eight most common irAEs, four were associated with superior survival, one borderline significant and three non-significant. Rheumatic irAEs and late-onset thyroid irAEs remained associated with improved OS after adjustment for negativ prognostic factors and immoral time bias. Colitis irAE were borderline significant in univariate analysis. Sarcoidosis-like and hypophysitis irAEs were rare but conferred excellent outcomes. Hepatitis, nephritis and pneumonitis were not associated with better survival. Most survival-associated irAE were treated with lower start dose of corticosteroids but duration and time to onset was similar to non–survival-associated irAEs. Conclusions Rheumatic, endocrine, and sarcoidosis-like irAEs as markers of superior survival and suggest that lower initial corticosteroid doses may preserve PD-1 inhibitor efficacy.
No takes yet. Share an insight, caveat, or question.
Linden et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: